Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine versus placebo for daytime neuropsychological effects in children with ADHD
2006-001470-25Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Strattera with Placebo (2 arms). Primary endpoint: Neuropsychological outcomes on computerized Continuous Performance Test. Started Jul 2007; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2006-001470-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001470-25.